Skip to main content
Fig. 5 | Diabetology & Metabolic Syndrome

Fig. 5

From: The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial

Fig. 5

Changes of glycemic status and insulin resistance after 26 weeks of treatment from baseline. Compared to placebo, empagliflozin has reduced all the markers of glycemic status after the treatment period (P > 001). FBS Fasting blood sugar, HbA1c Glycated Hemoglobin, HOMA-IR Homeostatic model assessment for insulin resistance

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us